NeuroTransit Overview
- Founded
-
2008
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
NeuroTransit General Information
Description
Owner and operator of a bio pharmaceutical company intended to offer therapeutics for neurologic, metabolic and oncologic diseases. The company bio pharmaceutical services include using proprietary technology for the development of drug products that cross the blood-brain barrier, enabling patients to avail treatment for neurologic, metabolic and oncologic diseases of the brain.
Contact Information
Website
www.neurotransit.com
Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
- 6020 Cornerstone West Court
- Suite 200
- San Diego, CA 92121
- United States
NeuroTransit Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 01-Feb-2018 | Completed | Out of Business | |||
| 1. Early Stage VC | 01-Jan-2013 | Completed | Startup |
NeuroTransit Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Michael Dunn | Co-Founder, President and Chief Executive Officer |